ARTIVION, INC. AORT

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NYSE

Artivion, Inc. ("Artivion," the "Company," "we," or "us"), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products ("On-X" products), surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Aortic arch stent grafts include our E-vita® Open NEO, E-vita Open Plus, Arcevo™ LSA Hybrid Stent Graft System ("Arcevo LSA"), the Ascyrus Medical Dissection Stent ("AMDS") hybrid prosthesis, the NEXUS ONETM ("NEXUS ONE"), NEXUS DUOTM ("NEXUS DUO"), and NEXUS TRETM ("NEXUS TRE") aortic arch stent graft systems (the "NEXUS family of products"), and E-vita Thoracic 3G products. Abdominal stent grafts include our E-xtra Design Engineering, E-nsideTM, ArtivexTM, E-tegraTM, E-ventusTM BX, TuvaTM BX, and E-liacTM products. Surgical sealants include BioGlue® Surgical Adhesive ("BioGlue") products. In addition to these four major product families, we sell or distribute PhotoFix® bovine surgical patches ("PhotoFix") and CardioGenesis® cardiac laser therapy (prior to our abandonment of the business as of June 30, 2023). We began to manufacture and supply PerClot® hemostatic powder ("PerClot") during the second quarter of 2023 (as part of the Transitional Manufacturing and Supply Agreement ("TMSA") of the Baxter Transaction).

Last close 25.57 2026-09-04
Market cap $1.25B 2026-06-30 share count
52-week range 19.16 - 48.25

Valuation FY2025 figures against the last close

P/S2.8x
P/E121.8x
P/FCF1,485.9x
EV/EBITDA24.9x
Dividend yield
Diluted EPS0.21

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $441.3M$388.5M$354.0M$313.8M$298.8M$253.2M$276.2M$262.8M$189.7M$180.4M
Cost of revenue $157.1M$139.8M$124.8M$111.3M$101.3M$85.4M$93.2M$89.9M$61.1M$61.5M
Gross profit $284.2M$248.8M$229.2M$202.5M$197.5M$167.8M$183.0M$173.0M$128.6M$118.9M
R&D $31.0M$28.5M$28.7M$38.9M$35.5M$24.2M$23.0M$23.1M$19.5M$13.4M
SG&A $226.5M$181.5M$209.0M$157.4M$169.8M$141.1M$143.0M$140.6M$101.2M$91.5M
Total operating expenses $257.5M$209.9M$237.7M$196.3M$205.3M$165.3M$166.0M$163.7M$120.7M$105.0M
Operating income $33.7M$38.9M$5.7M$6.2M$8.1M$2.4M$17.0M$9.3M$8.0M$21.8M
Interest expense $26.6M$34.3M$25.3M$18.2M$16.9M$16.7M$14.9M$15.8M$4.9M$3.0M
Pre-tax income $14.8M-$7.5M-$21.6M-$15.0M-$14.8M-$17.2M$1.6M-$6.4M$3.6M$18.4M
Income tax $5.0M$5.8M$9.1M$4.2M$7.0K$492.0K$76.0K$3.6M$143.0K$7.6M
Net income $9.8M-$13.4M-$30.7M-$19.2M-$14.8M-$16.7M$1.7M-$2.8M$3.7M$10.8M
EPS, basic 0.22-0.32-0.75-0.48-0.38-0.440.05-0.080.110.33
EPS, diluted 0.21-0.32-0.75-0.48-0.38-0.440.05-0.080.110.32
Shares, diluted (wtd. avg.) $47.2M$41.7M$40.7M$40.0M$39.0M$37.9M$37.9M$36.4M$34.2M$32.8M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $64.9M$53.5M$58.9M$39.4M$55.0M$62.0M$34.3M$42.2M$40.8M$57.3M
Receivables $89.8M$79.5M$71.8M$61.8M$53.0M$46.0M$52.9M$47.1M$47.5M$27.8M
Inventory $92.4M$79.8M$82.0M$74.5M$77.0M$73.0M$53.1M$45.5M$46.7M$26.3M
Total current assets $358.1M$290.1M$280.7M$247.3M$247.7M$234.6M$187.4M$179.2M$179.3M$147.2M
Property, plant and equipment $65.0M$36.4M$38.4M$38.7M$37.5M$33.1M$32.1M$31.0M$33.6M$18.5M
Goodwill $254.1M$241.0M$247.3M$243.6M$250.0M$260.1M$186.7M$188.8M$188.3M$78.3M
Other intangibles $123.7M$128.1M$142.6M$151.3M$167.0M$186.1M$115.4M$118.2M$130.4M$1.0M
Total assets $884.8M$789.1M$792.4M$762.8M$793.1M$789.4M$605.7M$571.1M$589.7M$316.1M
Accounts payable $16.0M$18.0M$13.3M$12.0M$10.4M$9.6M$9.8M$7.5M$9.8M$5.7M
Short-term debt $0$195.0K$1.5M$1.6M$1.6M$1.2M$1.2M$1.2M$718.0K$4.6M
Total current liabilities $101.6M$66.8M$57.9M$49.7M$45.0M$60.5M$45.2M$34.5M$42.9M$30.1M
Long-term debt $215.1M$314.2M$305.5M$306.5M$307.5M$290.5M$214.6M$215.7M$218.2M$67.0M
Total liabilities $436.6M$512.9M$510.6M$478.5M$492.3M$460.7M$320.0M$296.0M$312.6M$107.2M
Retained earnings -$51.5M-$61.3M-$47.9M-$17.2M$2.0M$20.0M$36.7M$35.0M$37.6M$34.1M
Total equity $448.2M$276.2M$281.8M$284.3M$300.7M$328.7M$285.7M$275.1M$277.1M$209.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $39.9M$22.2M$18.8M-$5.2M-$2.6M$12.4M$15.8M$9.9M$10.8M$19.7M
Depreciation and amortisation $22.5M$24.2M$23.1M$22.4M$24.0M$20.7M$18.3M$18.1M$9.7M$8.4M
Stock-based compensation $24.4M$14.2M$14.4M$12.3M$10.7M$6.9M$8.8M$6.3M$6.9M$6.3M
Capital expenditure $39.0M$11.2M$9.8M$10.7M$13.1M$7.3M$8.1M$5.8M$6.6M$6.2M
Investing cash flow -$42.0M-$28.2M-$502.0K-$10.7M$5.7M-$73.1M-$23.9M-$6.7M-$171.0M-$78.9M
Financing cash flow $11.3M$2.2M$865.0K-$1.6M-$12.2M$93.6M-$1.5M-$2.6M$143.2M$73.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-009046.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $116.27B 36.1x 11.2%
MMM 3M CO $86.93B 28.1x 1.5%
BSX BOSTON SCIENTIFIC CORP $69.27B 24.6x 19.9%
BDX BECTON DICKINSON & CO $50.32B 31.7x 8.2%
DXCM DEXCOM INC $33.17B 42.1x 15.6%
RMD RESMED INC $32.94B 21.9x 9.9%
MDLN Medline Inc. $31.35B 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $23.93B 50.1x 6.3%